author-photo

Chi-Chung Li

Merck & Co.

11

Papers

266

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor*

2020 Journal of Pharmacology and Experimental Therapeutics
Show All
- Source
- Cite
- Save
Citations (25)
The effect of multiple doses of ubrogepant on the pharmacokinetics of an oral contraceptive in healthy women: Results of an open-label, single-center, two-period, fixed-sequence study:

2020
Show All
- Source
- Cite
- Save
Citations (3)
Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males

2020 Clinical and Translational Science
Show All
- Source
- Cite
- Save
Citations (7)
Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase 2b Clinical Trials of Ubrogepant for Migraine Treatment

2019 Clinical and Translational Science
Show All
- Source
- Cite
- Save
Citations (2)
Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene-Related Peptide Receptor (P4.10-021)

2019 Neurology
Show All
- Source
- Cite
- Save
Citations (2)
Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist

2010 ACS Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (45)
Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist

2010 Journal of Pharmacology and Experimental Therapeutics
Show All
- Source
- Cite
- Save
Citations (67)